SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Mammalian Cells Expressing FMO
Award last edited on: 1/8/09

Sponsored Program
STTR
Awarding Agency
NIH : NIEHS
Total Award Amount
$885,000
Award Phase
2
Solicitation Topic Code
-----
Principal Investigator
Charles L Crespi

Company Information

Gentest Corporation

6 Henshaw Street
Woburn, MA 01801
   (781) 935-5115
   N/A
   www.gentest.com

Research Institution

Wake Forest University

Phase I

Contract Number: 1R41ES006973-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1994
Phase I Amount
$87,000
Rabbit FM01 and FM02 and human FM03 cDNAs will be expressed in AHH-1TK+/- human lymphoblastoid cells, AS52 Chinese hamster cells and C3H 10T1/2 mouse cells. FMO expression will be monitored by regio- and stereoselective/enzyme assays and immunoblotting. The level and stability of FMO expression will be monitored in the cDNA expressing cell lines. The differences in xenobiotic metabolism by allelic variants of human FM03 will be examined. The FMO-expressing human lymphoblastoid cell lines will compliment an existing panel of cell lines expressing cytochrome P450 enzymes. AS52 cells will allow the facile analysis of mutational spectrum for promutagens activated by FMO. The C3H 10T1/2 cell lines will allow extension of in vitro toxicology studies to the malignant transformation endpoint. PROPOSED COMMERCIAL APPLICATION: Mammalian cells expressing flavin- containing monoxygenases will have commercial applications for the in vitro analysis of xenobiotic metabolism and toxicity. This new system complements an existing system containing cytochrome P450 enzymes

Phase II

Contract Number: 2R42ES006973-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1996
(last award dollars: 1997)
Phase II Amount
$798,000
In Phase II Rabbit FM01 and FM02 and human FM03 cDNAs will be expressed in AHH-1TK+/- human lymphoblastoid cells, AS52 Chinese hamster cells and C3H 10T1/2 mouse cells. FMO expression will be monitored by regio- and stereoselective/enzyme assays and immunoblotting. The level and stability of FMO expression will be monitored in the cDNA expressing cell lines. The differences in xenobiotic metabolism by allelic variants of human FM03 will be examined. The FMO-expressing human lymphoblastoid cell lines will compliment an existing panel of cell lines expressing cytochrome P450 enzymes. AS52 cells will allow the facile analysis of mutational spectrum for promutagens activated by FMO. The C3H 10T1/2 cell lines will allow extension of in vitro toxicology studies to the malignant transformation endpoint. PROPOSED COMMERCIAL APPLICATION: Mammalian cells expressing flavin- containing monoxygenases will have commercial applications for the in vitro analysis of xenobiotic metabolism and toxicity. This new system complements an existing system containing cytochrome P450 enzymes